Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atea Pharmaceuticals Inc
(NQ:
AVIR
)
3.800
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atea Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 08, 2022
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharma's Investigational Dengue Treatment Fast Tracked In US
September 26, 2022
Via
Benzinga
Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir
September 13, 2022
Via
Benzinga
Recap: Atea Pharmaceuticals Q2 Earnings
August 08, 2022
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Short Volatility Alert: Atea Pharmaceuticals
May 18, 2022
On Tuesday, shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) experienced volatile short activity. After the activity, the stock price went down -1.73% to $7.38. The...
Via
Benzinga
Atea Pharmaceuticals Earnings Preview
November 04, 2022
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Atea...
Via
Benzinga
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
November 03, 2022
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022
October 31, 2022
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
July 07, 2022
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?
Via
Investor's Business Daily
Atea Pharmaceuticals: Q1 Earnings Insights
May 10, 2022
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Expert Ratings For Atea Pharmaceuticals
January 06, 2022
Atea Pharmaceuticals (NASDAQ:AVIR) has observed the following analyst ratin...
Via
Benzinga
Stocks Selling For Less Than Cash Per Share
July 03, 2022
How do you go about choosing a stock to buy in these volatile times? One strategy is to look for stocks that are not only selling below their book value, but also below their cash per share, especially...
Via
Talk Markets
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Preview For Atea Pharmaceuticals
May 09, 2022
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Atea...
Via
Benzinga
How To Attend Atea Pharmaceuticals Q1 2022 Earnings Conference Call
May 05, 2022
Atea Pharmaceuticals (NASDAQ:AVIR) will host a conference call at 10:00 AM ET on May 10, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
5 Value Stocks In The Healthcare Sector
April 25, 2022
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...
Via
Benzinga
NASDAQ:AVIR Investor Notice: Investigation over Potential Wrongdoing at Atea Pharmaceuticals, Inc.
April 05, 2022
San Diego, CA -- (SBWIRE) -- 04/05/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Atea Pharmaceuticals, Inc.
Via
SBWire
30 Stocks Moving in Tuesday's Pre-Market Session
March 15, 2022
Gainers Incannex Healthcare Limited (NASDAQ: IXHL) rose 118.2% to $49.97 in pre-market trading after jumping 54% on Monday. Incannex Healthcare recently completed a preliminary...
Via
Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
March 01, 2022
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday. GBS Inc. (NASDAQ: GBS) rose 73.3% to $0.7971 after declining around 9% on...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 01, 2022
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares rose 102.3% to $0.69 during Tuesday's pre-market session. The market value of their outstanding shares is at $14.3...
Via
Benzinga
27 Stocks Moving in Monday's Pre-Market Session
March 01, 2022
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 123.4% to $0.76 in pre-market trading after jumping 36% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB) rose 28.6...
Via
Benzinga
Atea Pharmaceuticals: Q4 Earnings Insights
February 28, 2022
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q4 earnings results on Monday, February 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
February 11, 2022
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.
Via
Investor's Business Daily
NASDAQ:AVIR Investor Notice: Investigation over Possible Securities Laws Violations by Atea Pharmaceuticals, Inc.
February 02, 2022
San Diego, CA -- (SBWIRE) -- 02/02/2022 -- Atea Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
February 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. (AVIR) Investigation
January 12, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
January 06, 2022
Upgrades For Canada Goose Holdings Inc (NYSE:
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.